Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)

The board of directors of the ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Company) announced that the group has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People's Republic of China (NMPA) for a randomized, double-blind, controlled Phase III clinical trial of IMM01 (Timdarpacept) in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome (HR MDS). Furthermore, the updated results of the Phase II clinical trial for IMM01 (Timdarpacept) in combination with azacitidine have been accepted as oral presentation at the 2024 American Society of Clinical Oncology (the "ASCO") meeting, to be presented in Chicago on June 1, 2024. The Group owns the global intellectual property rights and commercial rights of IMM01 (Timdarpacept).

As of the date of this announcement, in relation to IMM01 (Timdarpacept), the Group owned one patent family, which includes issued patents in China, the United States, Japan and the European Union.